Drug intelligence / Profile preview

iptakalim

Development stage: Preclinical
Lead developer: Institute of Pharmacology and Toxicology
Modality: Small Molecules
Administration: Oral, Intraperitoneal, Subcutaneous, Intravenous, Sublingual, Inhalation

Overview

Iptakalim is a novel ATP-sensitive potassium (KATP) channel opener. It has been shown to inhibit the proliferation of pulmonary arterial smooth muscle cells (PASMCs) and pulmonary vascular remodeling. In a rat model of chronic hypoxia-induced pulmonary hypertension, iptakalim significantly decreased pulmonary artery pressure and inhibited PKC-α overexpression. Its effects are mediated through KATP channels and involve the downregulation of PKC-α, suggesting its potential as a treatment for hypoxic pulmonary hypertension.

Other names: ITKL

Targets

KATP channel (ATP-sensitive potassium channel)

Beyond the preview

Go deeper on iptakalim.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iptakalim.

Explore the full profile